ES2392789T3 - Compuestos peptídicos para tratar las amiloidosis. - Google Patents

Compuestos peptídicos para tratar las amiloidosis. Download PDF

Info

Publication number
ES2392789T3
ES2392789T3 ES09761152T ES09761152T ES2392789T3 ES 2392789 T3 ES2392789 T3 ES 2392789T3 ES 09761152 T ES09761152 T ES 09761152T ES 09761152 T ES09761152 T ES 09761152T ES 2392789 T3 ES2392789 T3 ES 2392789T3
Authority
ES
Spain
Prior art keywords
peptide
compound
amino acid
acid sequence
cysteine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES09761152T
Other languages
English (en)
Spanish (es)
Inventor
Markus Mandler
Radmila Santic
Harald Weninger
Edith Kopinits
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Affiris AG
Original Assignee
Affiris AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Affiris AG filed Critical Affiris AG
Application granted granted Critical
Publication of ES2392789T3 publication Critical patent/ES2392789T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
ES09761152T 2008-06-12 2009-06-12 Compuestos peptídicos para tratar las amiloidosis. Active ES2392789T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AT9522008 2008-06-12
AT0095208A AT506820B1 (de) 2008-06-12 2008-06-12 Vakzine gegen alzheimer-krankheit
PCT/AT2009/000235 WO2009149485A2 (en) 2008-06-12 2009-06-12 Compounds for treating amyloidoses

Publications (1)

Publication Number Publication Date
ES2392789T3 true ES2392789T3 (es) 2012-12-13

Family

ID=41401983

Family Applications (1)

Application Number Title Priority Date Filing Date
ES09761152T Active ES2392789T3 (es) 2008-06-12 2009-06-12 Compuestos peptídicos para tratar las amiloidosis.

Country Status (14)

Country Link
US (1) US8409581B2 (enExample)
EP (1) EP2310033B1 (enExample)
JP (3) JP2011522840A (enExample)
KR (1) KR20110036039A (enExample)
CN (1) CN102123728B (enExample)
AT (2) AT509611B1 (enExample)
AU (1) AU2009257168B2 (enExample)
BR (1) BRPI0915136A2 (enExample)
CA (1) CA2723967A1 (enExample)
ES (1) ES2392789T3 (enExample)
IL (1) IL209894A (enExample)
MX (1) MX2010013657A (enExample)
RU (1) RU2491953C2 (enExample)
WO (1) WO2009149485A2 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120328605A1 (en) * 2010-10-27 2012-12-27 Daniel Larocque Compositions and uses
EP2686346B1 (en) * 2011-03-16 2016-12-14 Probiodrug AG Diagnostic antibody assay
GB201113570D0 (en) 2011-08-05 2011-09-21 Glaxosmithkline Biolog Sa Vaccine
EP2579042B1 (en) 2011-10-04 2014-07-09 Affiris AG Method for detecting Aß-specific antibodies in a biological sample
EP2659908A1 (en) 2012-05-01 2013-11-06 Affiris AG Compositions
US9102752B2 (en) 2013-03-15 2015-08-11 United Biomedical, Inc. Peptide vaccine for prevention and immunotherapy of dementia of the Alzheimer's type
EP2787347A1 (en) 2013-04-03 2014-10-08 Affiris AG Method for detecting Aß-specific antibodies in a biological sample
EP3137094B1 (en) 2014-04-29 2022-12-07 ADvantage Therapeutics, Inc. Treatment and prevention of alzheimer's disease (ad)
WO2015165964A1 (en) * 2014-04-29 2015-11-05 Affiris Ag Treatment and prevention of alzheimer's disease (ad)
WO2015165961A1 (en) 2014-04-29 2015-11-05 Affiris Ag Treatment and prevention of alzheimer's disease (ad)
CN108350052A (zh) 2015-11-09 2018-07-31 英属哥伦比亚大学 淀粉样蛋白β中间区域中的表位及其构象选择性抗体
JP7452829B2 (ja) 2015-11-09 2024-03-19 ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア アミロイドベータのエピトープおよびそれに対する抗体
EP3374379A4 (en) 2015-11-09 2019-05-15 The University Of British Columbia N-TERMINAL EPITOPES IN AMYLOID BETA AND CONFORMATION-SELECTIVE ANTIBODIES
WO2018014126A1 (en) 2016-07-18 2018-01-25 The University Of British Columbia Antibodies to amyloid beta
US20180125920A1 (en) 2016-11-09 2018-05-10 The University Of British Columbia Methods for preventing and treating A-beta oligomer-associated and/or -induced diseases and conditions
CA3070085A1 (en) 2017-07-18 2019-01-24 Promis Neurosciences Inc. Antibodies to amyloid beta
US12286469B2 (en) 2017-07-18 2025-04-29 The University Of British Columbia Humanized antibodies binding to amyloid-beta (A-beta)
RU2679080C1 (ru) * 2018-04-17 2019-02-05 Александр Олегович Морозов Пептид и способ лечения болезни альцгеймера
US20250186595A1 (en) 2022-02-28 2025-06-12 Tridem Bioscience Gmbh & Co Kg A CONJUGATE CONSISTING OF OR COMPRISING AT LEAST A ß-GLUCAN OR A MANNAN
CN115925987A (zh) * 2022-02-28 2023-04-07 安域生物科技(杭州)有限公司 基于β-淀粉样蛋白修饰的抗原多肽及其应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5780587A (en) * 1990-08-24 1998-07-14 President And Fellows Of Harvard College Compounds and methods for inhibiting β-protein filament formation and neurotoxicity
US7964192B1 (en) * 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
AU744044B2 (en) * 1998-04-06 2002-02-14 Advanced Immunit, Inc. Short peptides for treatment of neurological degenerative diseases
NO314086B1 (no) * 1998-05-08 2003-01-27 Gemvax As Peptider og farmasöytiske sammensetninger inneholdende disse, nukleinsyresekvenser som koder for slike peptider, plasmider og virusvektoreromfattende slike DNA-sekvenser samt anvendelse av disse for fremstilling avfarmasöytiske preparater til
CA2325600A1 (en) * 1998-05-21 1999-11-25 The University Of Tennessee Research Corporation Methods for amyloid removal using anti-amyloid antibodies
US7504490B1 (en) * 1998-10-16 2009-03-17 Oscient Pharmaceuticals Corporation Nucleic acid and amino acid sequences relating to Apergillus fumigatus for diagnostics and therapeutics
US20040067535A1 (en) * 2002-10-03 2004-04-08 Life Sciences Development Corp. Alzheimer's disease linked genes
CN101103969A (zh) * 2002-12-24 2008-01-16 神经化学（国际）有限公司 治疗β淀粉样蛋白相关疾病的治疗性制品
AT413945B (de) 2003-01-14 2006-07-15 Mattner Frank Dr Impfstoff für die alzheimer-krankheit
EP1440981A3 (en) * 2003-01-21 2005-11-23 Research Association for Biotechnology Full-length human cdna
US7358331B2 (en) 2003-05-19 2008-04-15 Elan Pharmaceuticals, Inc. Truncated fragments of alpha-synuclein in Lewy body disease
AT500483B1 (de) * 2004-07-13 2006-01-15 Mattner Frank Dr Set zur vorbeugung oder behandlung der alzheimer'schen erkrankung
AT413946B (de) * 2004-07-13 2006-07-15 Mattner Frank Dr Impfstoff gegen die alzheimer-krankheit
CN101137394A (zh) * 2004-10-25 2008-03-05 默克制药公司 抗addl抗体及其应用
EP1907416A2 (en) * 2005-06-17 2008-04-09 EPFL Ecole Polytechnique Fédérale de Lausanne Switch-peptides as tool for the study of fibrillogenesis
EP2808032B1 (en) * 2005-12-12 2018-08-01 AC Immune S.A. A beta 1-42 specific monoclonal antibodies with therapeutic properties
CA2638775A1 (en) * 2006-02-22 2007-08-30 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Peptide vaccine for inducing production of anti-amyloid-.beta.-peptide antibody

Also Published As

Publication number Publication date
BRPI0915136A2 (pt) 2019-09-24
JP2014139227A (ja) 2014-07-31
MX2010013657A (es) 2011-04-11
JP2011522840A (ja) 2011-08-04
CA2723967A1 (en) 2009-12-17
EP2310033A2 (en) 2011-04-20
AT506820B1 (de) 2011-07-15
AU2009257168A1 (en) 2009-12-17
CN102123728A (zh) 2011-07-13
RU2011100125A (ru) 2012-07-20
AU2009257168B2 (en) 2015-01-22
WO2009149485A2 (en) 2009-12-17
EP2310033B1 (en) 2012-09-05
AT509611A1 (de) 2011-10-15
IL209894A0 (en) 2011-02-28
JP5984867B2 (ja) 2016-09-06
RU2491953C2 (ru) 2013-09-10
US8409581B2 (en) 2013-04-02
WO2009149485A3 (en) 2010-06-10
AT509611B1 (de) 2012-04-15
KR20110036039A (ko) 2011-04-06
IL209894A (en) 2015-08-31
US20110171243A1 (en) 2011-07-14
JP5989074B2 (ja) 2016-09-07
JP2015110588A (ja) 2015-06-18
CN102123728B (zh) 2017-05-31
AT506820A1 (de) 2009-12-15

Similar Documents

Publication Publication Date Title
ES2392789T3 (es) Compuestos peptídicos para tratar las amiloidosis.
ES2461492T3 (es) Péptidos para tratar las beta-amiloidosis
ES2962346T3 (es) Mimotopo
US20110092436A1 (en) Compounds for treating symptoms associated with parkinson's disease
RU2532351C2 (ru) Применение мимеотопов альфа-синуклеиновых эпитопов для лечения заболеваний, связанных с тельцами леви
HK1152470B (en) Peptides for treating beta-amyloidoses